Data from our group, studying cell samples obtained from 57 CML patients showed that 79% of the samples presented reduced levels of mRNA for SLC22A1. Unfortunately, at that time no correlation was made with imatinib clinical responses (R.C. Maia, unpublished work). Here, SLC22A1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.